{"organizations": [], "uuid": "e4f0e3afbc6155340fd77d9cded3dddf95613322", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180214.html", "section_title": "Archive News &amp; Video for Wednesday, 14 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-amgen-announces-fda-advisory-commi/brief-amgen-announces-fda-advisory-committee-meeting-to-review-potential-new-use-of-blincyto-idUSFWN1Q41KO", "country": "US", "domain_rank": 408, "title": "BRIEF-Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of Blincyto", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.004, "site_type": "news", "published": "2018-02-15T05:07:00.000+02:00", "replies_count": 0, "uuid": "e4f0e3afbc6155340fd77d9cded3dddf95613322"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-amgen-announces-fda-advisory-commi/brief-amgen-announces-fda-advisory-committee-meeting-to-review-potential-new-use-of-blincyto-idUSFWN1Q41KO", "ord_in_thread": 0, "title": "BRIEF-Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of Blincyto", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda advisory committee meeting to review potential new use of blincyto", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "amgen inc", "sentiment": "negative"}, {"name": "fda advisory committee", "sentiment": "negative"}, {"name": "amgen", "sentiment": "negative"}, {"name": "blincyto", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - Amgen Inc:\n* AMGEN ANNOUNCES FDA ADVISORY COMMITTEE MEETING TO REVIEW POTENTIAL NEW USE OF BLINCYTOÂ® (BLINATUMOMAB)\n* AMGEN INC - FDA ADVISORY COMMITTEE MEETING TO REVIEW POTENTIAL NEW USE OF BLINCYTO AT A MEETING ON MARCH 7 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T05:07:00.000+02:00", "crawled": "2018-02-15T20:48:58.002+02:00", "highlightTitle": ""}